InterCure Ltd. (INCR)vsMerck & Company Inc (MRK)
INCR
InterCure Ltd.
$5.16
-1.53%
HEALTHCARE · Cap: $81.02M
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 27281% more annual revenue ($66.57B vs $243.12M). MRK leads profitability with a 4.8% profit margin vs -13.2%. INCR earns a higher WallStSmart Score of 38/100 (F).
INCR
Hold38
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INCR.
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 23.9% year-over-year
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Operating margin of 0.0%
ROE of -9.0% — below average capital efficiency
Earnings declined 84.7%
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : INCR
The strongest argument for INCR centers on Price/Book, Revenue Growth. Revenue growth of 23.9% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : INCR
The primary concerns for INCR are Market Cap, Operating Margin, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
INCR profiles as a growth stock while MRK is a value play — different risk/reward profiles.
INCR carries more volatility with a beta of 0.57 — expect wider price swings.
INCR is growing revenue faster at 23.9% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
INCR scores higher overall (38/100 vs 36/100) and 23.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
InterCure Ltd.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Syneos Health, Inc., a contract research organization, provides various clinical development services for the medical device and biopharmaceutical industries in North America, Europe, the Middle East and Africa, Asia-Pacific, and Latin America. The company is headquartered in Raleigh, North Carolina.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?